Laboratory evaluations of the 3-month efficacy of oral lotilaner (Credelio™) against experimental infestations of dogs with the Australian paralysis tick, Ixodes holocyclus

• Published in: Parasites & vectors Vol. 11; no. 1; pp. 487 - 6
• Main Authors: Baker, Kim, Ellenberger, Claudia, Murphy, Martin, Cavalleri, Daniela, Seewald, Wolfgang, Drake, Jason, Nanchen, Steve, Hacket, Kristina
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.08.2018; BioMed Central; BMC
• Subjects: Administration, Oral; Animals; Arachnids; Australia - epidemiology; Carrying capacity; Causes of; Control; Credelio; Dog; Dog diseases; Dog Diseases - drug therapy; Dog Diseases - parasitology; Dogs; Dosage; Dosage and administration; Duration; Effectiveness; Female; Hard ticks; Health aspects; Infestation; Insecticides - administration & dosage; Insecticides - adverse effects; Insecticides - therapeutic use; Isoxazoles - administration & dosage; Isoxazoles - adverse effects; Isoxazoles - therapeutic use; Ixodes - drug effects; Ixodes holocyclus; Laboratories; Laboratories - statistics & numerical data; Lotilaner; Male; Neurotoxins; Neurotoxins - metabolism; Neurotoxins - therapeutic use; Paralysis; Paralysis tick; Parasitology; Pesticides; Pets; Prevention; Sheep; Studies; Tablets; Testing; Tick Infestations - drug therapy; Tick Infestations - epidemiology; Tick Infestations - veterinary; Tick Paralysis - drug therapy; Tick Paralysis - epidemiology; Tick Paralysis - parasitology; Tick Paralysis - veterinary; Ticks; Time Factors; Veterinary drugs; Veterinary insecticides; Australia; Queensland Australia; Ixodes holocyclus; Credelio; Lotilaner; Paralysis tick; Dog
• ISSN: 1756-3305; 1756-3305
• DOI: 10.1186/s13071-018-3061-8

From three days following host attachment, the Australian paralysis tick, Ixodes holocyclus, secretes a neurotoxin that annually causes paralysis in approximately 10,000 domestic pets. Lotilaner, a novel isoxazoline formulated in a chewable flavoured tablet (Credelio ), produces rapid onset of acaricidal activity in dogs, with an efficacy duration of at least one month. Two studies were performed to determine the efficacy of lotilaner against I. holocyclus infestations over 3 months. Both studies included 16 dogs, ranked according to I. holocyclus counts on Day -5 (from infestations on Day -8) and blocked into pairs. One dog in each pair was randomized to be a sham-treated control, the other to receive lotilaner at a minimum dose rate of 20 mg/kg on Day 0. Dogs were dosed in a fed state. Infestations were performed in both studies on Days -8 (to determine the tick carrying capacity of each dog) -1, 28, 56, 70, 77 and 84, and additionally in Study 1 on Day 91, in Study 2 on Days 14 and 42. In Study 1, ticks were counted and assessed as alive or dead at 24, 48 and 72 h post-initial infestation and post-subsequent re-infestations. In study 2, ticks were counted at 24, 48 and 72 h post-dosing or post-re-infestation. Efficacy was determined by the percent reduction in live attached tick counts in the lotilaner group compared to control. Within 48 h post-treatment in Study 1 and within 72 h post-treatment in Study 2 all lotilaner-group dogs were free of live ticks. By 72 h post-infestation, efficacy in Study 1 remained at 100% through Day 87, except on Day 31 when a single tick was found on one dog, and through Day 59 in Study 2. Efficacy exceeded 95% through the final assessment in each study (Days 94 and 87 in Studies 1 and 2, respectively). These results demonstrate that lotilaner quickly kills existing I. holocyclus infestations. By providing 95.3-100.0% protection through at least 87 days post-treatment, lotilaner can be a valuable tool in reducing the risk of tick paralysis in dogs.